Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    " July 27, 2011":" August 26, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA HIVIS and MVA-CMDR;   Biological: Saline solution
2 Recruiting the ANRS CO21 " Extreme " Cohort (CODEX)
Condition: HIV Infection
Intervention: Biological: blood sampling
3 Completed Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
Condition: HIV Infections
Interventions: Biological: Sub C gp140 Vaccine;   Biological: MF59C.1 Adjuvant;   Other: Sodium chloride
4 Completed An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
Condition: Human Immunodeficiency Virus; HIV
Interventions: Drug: Darunavir/Ritonavir (DRV/r);   Drug: Efavirenz (EFV)
5 Completed Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV
Condition: HIV-infection
Intervention: Drug: Angiotensin II Infusion
6 Active, not recruiting Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care
Condition: HIV-infection/Aids
Intervention: Behavioral: Health Navigator
7 Completed Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events
Condition: HIV-Infection
Intervention: Other: Time of starting antiretroviral therapy
8 Terminated Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Conditions: Human Immunodeficiency Virus;   Lipohypertrophy
Intervention: Drug: Raltegravir-Maraviroc
9 Unknown  HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users
Conditions: HIV;   Drug Use Disorders
Interventions: Behavioral: HEART to HAART;   Behavioral: adherence counseling with the addition of smartphone control
10 Completed DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects
Condition: HIV
Interventions: Drug: Twice-daily Darunavir/ritonavir;   Drug: Once-daily Darunavir/ritonavir
11 Completed Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction
Condition: HIV
Intervention: Dietary Supplement: Moringa oleifera
12 Completed
Has Results
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers
Conditions: Hepatitis C;   HIV
Intervention: Drug: boceprevir; etravirine
13 Completed
Has Results
Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi
Condition: HIV
Interventions: Other: Home assessment and initiation of ART;   Other: Clinic-based ART assessment and initiation
14 Active, not recruiting Eplerenone in HIV Associated Abdominal Fat Accumulation
Condition: HIV
Interventions: Drug: Eplerenone and lifestyle;   Other: placebo and lifestyle
15 Completed Targeting Interventions at Venues Where Risk of HIV Transmission is High
Condition: HIV
Intervention: Other: Condom distribution and peer education
16 Completed HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
Conditions: HIV Infection;   Hepatitis C
Intervention:
17 Completed AIMS Study: Improving HIV Treatment Adherence
Condition: HIV
Interventions: Behavioral: Treatment as usual;   Behavioral: AIMS intervention
18 Completed
Has Results
Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects
Condition: HIV
Interventions: Drug: Atazanavir (current formulation);   Drug: Atazanavir, powder for oral use 1 (POU1);   Drug: Atazanavir (POU2)
19 Completed Integrated Mental Health Treatment & HIV Prevention for Court-Involved Youth
Condition: HIV Prevention
Interventions: Behavioral: Integrated treatment program;   Behavioral: Treatment as Usual
20 Completed Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% vaginal gel;   Drug: Depo-medroxyprogesterone acetate (DMPA);   Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.